Andrew TSOTINIS

Prof. Andrew TSOTINIS

Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian, University of Athens, Greece
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MVMarilena Vlachou
Marilena Vlachou
SKStefanos Kikionis
Stefanos Kikionis
Angeliki SiamidiAngeliki Siamidi
Angeliki Siamidi
SKSotiria Kyriakou
Sotiria Kyriakou
Andrew TSOTINISAndrew TSOTINIS
Andrew TSOTINIS
Vassilios RoussisVassilios Roussis
Vassilios Roussis
Furosemide, a chloride channel blocker ordinarily used as a high-ceiling or loop diuretic, is practically insoluble in water and dilute acids. Due to its acidic nature, furosemide is mostly absorbed in the stomach and in the upper small intestine. Efforts have focused on the development of sustained release systems of furosemide in order to improve the effectiveness of the drug, which exhibits poor aqueous solubility and poor permeability. Recently, electrospun nanofibrous drug delivery systems have emerged as promising alternative solid-dosage forms due to their advantages of high porosity, high surface to volume ratio, and high drug-loading efficacy. Herein, a number of nanofibrous mats composed of different types of Eudragit® polymers in various concentrations and combinations loaded with furosemide were designed, successfully electrospun, and characterized using SEM, FTIR, DSC, and TGA analyses. The nanofibrous nonwovens were formulated in nanofiber tablets and the release profile of furosemide from them was evaluated at pH 1.2 and 6.8 and compared to that of physical mixture matrix tablets of analogous composition as well as to that of a commercial formulation. It was found that the release of furosemide was compatible with the gastroretentive and slower intestinal release requirements with a well-defined absorption window, while some nanofiber formulations could act as furosemide carriers in emergency situations where a relatively fast onset of its action is required, as in the case of critically ill post-traumatic patients.

9 May 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Andrew TSOTINISAndrew TSOTINIS
Andrew TSOTINIS
MVMargarita Vlachou
Margarita Vlachou
DPDemetris P. Papahatjis
Demetris P. Papahatjis
TCTheodora Calogeropoulou
Theodora Calogeropoulou
SNSpyros P. Nikas
Spyros P. Nikas
DSDavid Sugden
David Sugden


20 July 2005 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CSCharikleia Souli
Charikleia Souli
NANicolaos Avlonitis
Nicolaos Avlonitis
TCTHEODORA CALOGEROPOULOU
THEODORA CALOGEROPOULOU
Andrew TSOTINISAndrew TSOTINIS
Andrew TSOTINIS
GMGábor Maksay
Gábor Maksay
MPManthos Papadopoulos
Manthos Papadopoulos

8 November 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Andrew TSOTINISAndrew TSOTINIS
Andrew TSOTINIS
PAPandelis A. Afroudakis
Pandelis A. Afroudakis
KDKathryn Davidson
Kathryn Davidson
APAnjali Prashar
Anjali Prashar
DSDavid Sugden
David Sugden

1 July 2007 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Andrew TSOTINISAndrew TSOTINIS
Andrew TSOTINIS
MPMaria Panoussopoulou
Maria Panoussopoulou
AEAndreas Eleutheriades
Andreas Eleutheriades
KDKathryn Davidson
Kathryn Davidson
DSDavid Sugden
David Sugden